Patent application number | Description | Published |
20140158950 | SURFACE CHEMICAL MODIFICATION OF NANOCRYSTALS - Nanocrystals comprising organic ligands at surfaces of the plurality of nanocrystals are provided. The organic ligands are removed from the surfaces of the nanocrystals using a solution comprising a trialkyloxonium salt in a polar aprotic solvent. The removal of the organic ligands causes the nanocrystals to become naked nanocrystals with cationic surfaces. | 06-12-2014 |
20140220362 | ELECTROCHROMIC NANOCOMPOSITE FILMS - The present invention provides an electrochromic nanocomposite film. In an exemplary embodiment, the electrochromic nanocomposite film, includes (1) a solid matrix of oxide based material and (2) transparent conducting oxide (TCO) nanostructures embedded in the matrix. In a further embodiment, the electrochromic nanocomposite film farther includes a substrate upon which the matrix is deposited. The present invention also provides a method of preparing an electrochromic nanocomposite film. | 08-07-2014 |
20150062687 | NANOCRYSTAL-POLYMER NANOCOMPOSITE ELECTROCHROMIC DEVICE - Described is an electrochromic nanocomposite film comprising a solid matrix of an oxide based material, the solid matrix comprising a plurality of transparent conducting oxide (TCO) nanostructures dispersed in the solid matrix and a lithium salt dispersed in the solid matrix. Also described is a near infrared nanostructured electrochromic device having a functional layer comprising the electrochromic nanocomposite film. | 03-05-2015 |
20150109652 | NANOSTRUCTURED TRANSPARENT CONDUCTING OXIDE ELECTROCHROMIC DEVICE - The embodiments described herein provide an electrochromic device. In an exemplary embodiment, the electrochromic device includes (1) a substrate and (2) a film supported by the substrate, where the film includes transparent conducting oxide (TCO) nanostructures. In a further embodiment, the electrochromic device further includes (a) an electrolyte, where the nanostructures are embedded in the electrolyte, resulting in an electrolyte, nanostructure mixture positioned above the substrate and (b) a counter electrode positioned above the mixture. In a further embodiment, the electrochromic device further includes a conductive coating deposited on the substrate between the substrate and the mixture. In a further embodiment, the electrochromic device further includes a second substrate positioned above the mixture. | 04-23-2015 |
Patent application number | Description | Published |
20100254948 | PROCESS FOR THE PREPARATION OF GAMMA-AMINO BUTYRIC ACID (GABA) BY THE USE OF LACTIC ACID BACTERIA (LAB) ON AGRO-AND FOOD-INDUSTRY SURPLUS - This invention relates to a process for the production of gamma-aminobutyric acid (GABA) from | 10-07-2010 |
20120034339 | PROCESS OF MICROBIC BIOTECHNOLOGY FOR COMPLETELY DEGRADING GLUTEN IN FLOURS - The present invention concerns the use of lactic acid bacteria selected and fungal enzymes for the gluten complete degradation from both bread and durum wheat, barley, rye and oat flour. In particular, the invention concerns the use of lactic acid bacteria selected and fungal enzymes for the gluten complete degradation (residual gluten concentration lower than 20 ppm) of cereal flours, which after detoxification can be used according to a standardized biotechnological protocol for the production of various gluten-free foods. | 02-09-2012 |
20130059790 | PROCESS FOR THE PREPARATION OF A BIOMASS COMPRISING PLANTARICIN AND USES THEREOF IN MEDICAL FIELD - The present invention concerns a process for preparation of a biomass comprising one or a more plantaricins A, N or K in association with the lactic acid bacteria used for the preparation and uses thereof in order to stimulate the barrier function of intestinal cells or human epidermal keratinocytes. | 03-07-2013 |
20130231291 | FERMENTED SOYA BASED MIXTURE COMPRISING ISOFLAVONES- AGLICONES, EQUOL AND LUNASIL, PROCESS FOR THE PREPARATION AND USES THEREOF IN FOOD, MEDICAL AND COSMETIC FIELDS - The present invention concerns a mixture comprising isoflavones-aglicones, such as daidzein, genistein and glycitein, in addition to equol and lunasin, said mixture being based on soya fermented using lactic acid bacteria isolated from food matrices and use of said mixture for protection of skin and similar and of human intestinal cells with particular reference to prevention of inflammatory state and protection of barrier functions and hair loss treatment. | 09-05-2013 |
20140065262 | METHOD FOR PARTIAL DEGRADATION OF GLUTEN - The present invention is directed to a method for preparing flour dough with reduced content of gluten starting from gluten containing cereals flours. In particular, the invention is directed to the use of lactic acid bacteria and fungal enzymes for the partial degradation of gluten in wheat flour in order to obtain flour dough with residual gluten concentration from 20,000-80,000 ppm. The flour dough obtained by the method of the invention can be used to prepare food products with reduced gluten content. | 03-06-2014 |
20140348807 | PROCESS FOR THE PREPARATION OF A BIOMASS COMPRISING PLANTARICIN AND USES THEREOF IN MEDICAL FIELD - The present invention concerns methods for administering to a subject plantaricins A, N or K and/or a biomass having at least one plantaricin selected from plantaricins A. K or N or mixtures thereof and | 11-27-2014 |
Patent application number | Description | Published |
20100047253 | FULLY HUMAN MONOCLONAL ANTIBODIES TO IL-13 - The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided. | 02-25-2010 |
20100183616 | Antibodies against interleukin-1 beta - Antibodies directed to the antigen IL-1β and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1β. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 07-22-2010 |
Patent application number | Description | Published |
20110118245 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O) | 05-19-2011 |
20130296363 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS - Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 11-07-2013 |
20140045868 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. | 02-13-2014 |
Patent application number | Description | Published |
20080247965 | PRESSURISED METERED DOSE INHALERS (MDI) - The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005. | 10-09-2008 |
20090311196 | PHARMACEUTICAL AEROSOL COMPOSITION - Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol. | 12-17-2009 |
20100098642 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 04-22-2010 |
20110100361 | PRESSURISED METERED DOSE INHALERS (MDI) - The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005. | 05-05-2011 |
20110212912 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 09-01-2011 |
20120184502 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 07-19-2012 |
Patent application number | Description | Published |
20090216120 | Method for Measuring Hydration of Soft Tissue - The disclosure relates to a method of measuring tissue hydration or a bodily fluid such a lymph or interstitial fluid. In the method, at least one elastographic parameter of a tissue or bodily fluid may be measured to obtain an elastographic parameter measurement that correlates with a mechanical, pathological, physiological or functional property of the tissue or bodily fluid. The elastographic parameter measurement may be correlated with a tissue hydration value or bodily fluid value, including quantitative tissue hydration or bodily fluid values. Multiple measurements taken over time may be used to detect changes in tissue hydration, amounts of bodily fluid, bodily fluid movement, or rate of clearance of a bodily fluid. The disclosure also relates to a device containing a ultrasound transducer, circuitry able to perform methods of the disclosure, and a display able to display tissue hydration or bodily fluid information. | 08-27-2009 |
20090301204 | Methods For Imaging Displacement Of A Target Body - The invention is directed toward a new method for estimating and imaging the spatial and temporal mechanical behavior of materials in responses to a mechanical stimulus. This method is designed to work in inherently noisy applications, such as the imaging of the time-dependent mechanical behavior of biological tissues in vivo and using a preferred hand-held configuration of scanning. | 12-10-2009 |
20100010353 | Methods For Determining Displacement Or Strain Of A Target Body - The invention is directed toward a new method for estimating and imaging the spatial and temporal mechanical behavior of materials in responses to a mechanical stimulus. This method is designed to work in inherently noisy applications, such as the imaging of the time-dependent mechanical behavior of biological tissues in vivo and using a preferred hand-held configuration of scanning. | 01-14-2010 |
20100180684 | Methods For Measuring Mechanical Stimulus - The invention is directed toward a new method for estimating and imaging the spatial and temporal mechanical behavior of materials in responses to a mechanical stimulus. This method is designed to work in inherently noisy applications, such as the imaging of the time-dependent mechanical behavior of biological tissues in vivo and using a preferred hand-held configuration of scanning. | 07-22-2010 |
20100251820 | Method For Imaging Strain Of A Target Body - The invention is directed toward a new method for estimating and imaging the spatial and temporal mechanical behavior of materials in responses to a mechanical stimulus. This method is designed to work in inherently noisy applications, such as the imaging of the time-dependent mechanical behavior of biological tissues in vivo and using a preferred hand-held configuration of scanning. | 10-07-2010 |
Patent application number | Description | Published |
20100056813 | PROCESS FOR PREPARING NEBIVOLOL - The present invention relates to a process for preparing nebivolol and, more particularly, to a process for preparing d-nebivolol and its enantiomer l-nebivolol or acid addition salts thereof starting from commercially available or easily obtainable 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde and a vinyl Grignard reagent. | 03-04-2010 |
20100069652 | The Process for Preparing Nebivolol - The present invention relates to a process for the preparation of Nebivolol and, more particularly, to an improved method of synthesizing 6-fluoro chroman epoxides of formula (I) key intermediates in preparing nebivolol. | 03-18-2010 |
20110021793 | PROCESS FOR PREPARING NEBIVOLOL - The present invention relates to a process for reducing a compound of formula (I) wherein X is halogen, a hydroxy group, an alkylsulfoniloxy group or an arylsulfonyloxy group; to give a compound of formula (II) as a di-astereoisomerically pure compound of RS/SR configuration characterized in that said reduction is carried out by the use of (+)-B-chlorodiisopinocampheylborane or (−)-B-chlorodiisopinocampheylborane. The compounds of formula (II) are useful as intermediates for the preparation of Nebivolol. | 01-27-2011 |
20110201831 | PROCESS FOR PREPARING NEBIVOLOL - The present invention relates to a process for preparing nebivolol and, more particularly, to a process for preparing d-nebivolol and its enantiomer l-nebivolol or acid addition salts thereof starting from commercially available or easily obtainable 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde and a vinyl Grignard reagent. | 08-18-2011 |
20110207948 | PROCESS FOR PREPARING NEBIVOLOL - The present invention relates to a process for preparing Nebivolol and, more particularly, to an improved method of debenzylation of a compound of formula (II) useful for preparing nebivolol endowed with high purity. | 08-25-2011 |
20130253195 | PROCESS FOR PREPARING BOSENTAN MONOHYDRATE AND ITS INTERMEDIATED - The present invention relates to a process for preparing Bosentan Monohydrate; in particular, the present invention provides the preparation of the novel 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yl]-benzenesulfonamide sodium salt as an ethylene glycol solvate (Bosentan sodium salt ethylene glycol solvate), which is a useful intermediate for obtaining Bosentan Monohydrate in a pure form. | 09-26-2013 |
20130338377 | ASYMMETRIC REDUCTION PROCESS - The present invention relates to a stereoselective reduction procedure to obtain, by means of catalytic asymmetric hydrogenation by hydrogen transfer, a compound of formula (I) in which X is S or SO | 12-19-2013 |